CSP
ESPR

Cary Street Partners’s Esperion Therapeutics ESPR Stock Holding History

Cary Street Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,175
Closed -$37.6K – 999
2025
Q4 		$37.6K Buy
+10,175
New +$32.9K ﹤0.01% 947

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cary Street Partners's ESPR Position: Q1 2026 in Review

Cary Street Partners sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 10,175 shares — an estimated $37.6K sold.

Cary Street Partners first reported a position in ESPR in Q4 2025 and held it in 1 quarter. The position peaked at $37.6K in Q4 2025. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Cary Street Partners reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cary Street Partners sold 10,175 Esperion Therapeutics shares in Q1 2026, an estimated $37.6K.
  • Cary Street Partners first reported a position in Esperion Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cary Street Partners's Esperion Therapeutics position peaked at $37.6K in Q4 2025.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Cary Street Partners's 13F filing for Q1 2026, filed 29 Apr 2026.